Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Amgen Inc. is conducting a Phase 4 clinical study titled ‘A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China.’ The study aims to evaluate the efficacy of Prolia on lumbar spine bone mineral density (BMD) over a 12-month period. This research is significant as it addresses osteoporosis treatment specifically in male patients, a demographic often underrepresented in osteoporosis studies.
Intervention/Treatment: The study tests Prolia, a drug administered via subcutaneous injections every six months. Prolia is intended to improve bone density and reduce fracture risk in osteoporosis patients.
Study Design: This is an interventional study with a single-group assignment model, meaning all participants receive the same treatment without a control group. There is no masking, indicating that both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on August 6, 2024, with primary completion expected 12 months later. The latest update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study update could positively impact Amgen’s stock performance by reinforcing investor confidence in Prolia’s market potential, especially in the growing Chinese market. Success in this study may also position Amgen favorably against competitors in the osteoporosis treatment sector.
The study is ongoing, with further details available on the ClinicalTrials portal.